We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Read MoreHide Full Article
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) shares rallied 11.2% in the last trading session to close at $26.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.4% loss over the past four weeks.
The recent price rise can be attributed to growing investor confidence related to the sales performance of the company’s flagship product, Zoryve (topical roflumilast), a highly potent and selective phosphodiesterase-4 inhibitor marketed in the United States in both cream and foam formulations. Zoryve is approved across three major inflammatory dermatological conditions—plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis recorded product sales worth $235.3 million in the first half of 2026, surging nearly 62% year over year.
This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +183.3%. Revenues are expected to be $141.64 million, up 42.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Arcutis Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARQT going forward to see if this recent jump can turn into more strength down the road.
Arcutis Biotherapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, TG Therapeutics (TGTX - Free Report) , finished the last trading session 5.3% higher at $55.85. TGTX has returned 5.5% over the past month.
TG Therapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.36. Compared to the company's year-ago EPS, this represents a change of -85.2%. TG Therapeutics currently boasts a Zacks Rank of #5 (Strong Sell).
View the Zacks #1 Rank List
Image: Bigstock
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) shares rallied 11.2% in the last trading session to close at $26.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.4% loss over the past four weeks.
The recent price rise can be attributed to growing investor confidence related to the sales performance of the company’s flagship product, Zoryve (topical roflumilast), a highly potent and selective phosphodiesterase-4 inhibitor marketed in the United States in both cream and foam formulations. Zoryve is approved across three major inflammatory dermatological conditions—plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis recorded product sales worth $235.3 million in the first half of 2026, surging nearly 62% year over year.
This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +183.3%. Revenues are expected to be $141.64 million, up 42.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Arcutis Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARQT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Arcutis Biotherapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, TG Therapeutics (TGTX - Free Report) , finished the last trading session 5.3% higher at $55.85. TGTX has returned 5.5% over the past month.
TG Therapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.36. Compared to the company's year-ago EPS, this represents a change of -85.2%. TG Therapeutics currently boasts a Zacks Rank of #5 (Strong Sell).